# Microfluidic Devices Market > 微流体设备市场研究报告：按应用（体外诊断、药物递送、即时检测、生物医学研究）、按材料类型（聚合物、玻璃、硅、金属）、按技术（压力驱动、电动流体、毛细管驱动、磁流体）、按最终用途（医疗保健、制药、环境检测、学术研究）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长前景与行业预测2025至2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.25% - **2024:** $ 6.99 Billion - **2025:** $ 7.64 Billion - **2035:** $ 18.5 Billion - **Key Players:** Companies such as Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Danaher Corporation (US), PerkinElmer (US), Fluidigm Corporation (US), Bio-Rad Laboratories (US), MilliporeSigma (US), Micronit Microfluidics (NL), Dolomite Microfluidics (GB) are some of the major players in the market. **Report ID:** MRFR/MED/0448-CR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/microfluidic-devices-market-954 --- ## Market Summary Global Microfluidic Devices Market Size was valued at USD 6.99 Billion in 2024 & the market is projected to grow from USD 7.637 Billion in 2025 to USD 18.5 Billion by 2035, registering a CAGR of 9.20% during the forecast period 2025–2035. North America led the market with over 44.35% share, generating around USD 3.1 Billion in revenue.   Rising demand for personalized medicine is a major growth driver for the Microfluidic Devices Market. Microfluidic platforms enable precise biomarker analysis, customized diagnostics, and targeted therapeutic development, supporting individualized treatment strategies while improving clinical efficiency, patient outcomes, and healthcare decision-making worldwide.   According to the World Health Organization, noncommunicable diseases account for approximately 43 million deaths annually worldwide, representing nearly 75% of all non-pandemic deaths. This growing chronic disease burden is accelerating demand for personalized diagnostic technologies, creating significant opportunities for microfluidic device adoption. ## Market Drivers ### Rising Demand for Personalized Medicine 微流控设备行业正经历个性化医疗需求的显著增长。这一趋势源于对满足个体患者特征的定制治疗方法需求的日益认可。微流控设备促进了个性化诊断和治疗方案的开发，使医疗提供者能够提供更有效的护理。 根据最近的估计，全球个性化医疗市场预计到2025年将达到2万亿美元，显示出强劲的增长轨迹。这一增长可能推动微流控设备行业的发展，因为这些技术对于定制药物输送系统和诊断工具的开发至关重要。随着医疗系统越来越多地采用个性化方法，全球市场有望从这一范式转变中显著受益。 - 根据IHME的数据，慢性疾病占全球疾病负担的主要部分，导致对精准医疗方法的需求不断增长。癌症、心血管疾病和代谢疾病的日益普遍加速了个性化诊断工具的采用，加强了微流控技术在靶向治疗规划中的机会。 ### Advancements in Lab-on-a-Chip Technology 实验室芯片技术的进展正在显著影响微流控设备行业。这些创新使得将多个实验室功能集成到单一芯片上，从而提高各种分析过程的效率和速度。实验室芯片设备越来越多地用于[临床诊断](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770)、药物发现和环境监测。最近的数据表明，实验室芯片市场预计在未来几年将以约20%的复合年增长率增长。 这一增长表明微流控技术在多种应用中的采用不断上升，这可能推动对微流控设备的需求。随着这些技术的不断发展，全球市场预计将见证实质性的进步，从而改善医疗结果和运营效率。 - PubMed研究表明，实验室芯片平台可以将样本体积减少90%以上，同时显著加快分析工作流程。这些优势正在推动在诊断、药物发现和生物医学研究中的采用，加强了对先进微流控设备在医疗和生命科学应用中的需求。 ### Emergence of Wearable Microfluidic Devices 可穿戴微流控设备的出现有望改变微流控设备行业。这些创新设备能够持续监测生理参数，为用户提供实时健康数据。微流控技术与可穿戴技术的结合正在促进健康监测、慢性病管理和健身追踪的进步。 最近的预测表明，[可穿戴医疗设备](https://www.marketresearchfuture.com/reports/wearable-medical-device-market-899)市场到2025年可能超过300亿美元，突显了微流控应用在该领域的潜力。随着消费者越来越寻求便捷高效的健康监测解决方案，对可穿戴微流控设备的需求可能会上升。这一趋势表明，全球市场将继续发展，受到创新健康解决方案需求的推动，从而增强用户参与度和健康结果。 - 在PubMed上发表的研究强调了可穿戴生物传感技术的临床采用不断增加，这些技术能够通过汗液和间质液持续监测生物标志物。微流控技术与可穿戴健康系统的结合支持实时生理监测和个性化疾病管理，扩展了未来市场机会。 ### Growing Focus on Point-of-Care Diagnostics 微流控设备市场正在见证对即时诊断的关注日益增加，这正在重塑医疗测试的格局。即时检测允许在患者护理现场快速诊断和治疗，显著改善患者结果。微流控设备在这一趋势中发挥着关键作用，使得便携和高效的诊断工具的开发成为可能。 全球即时诊断市场预计到2026年将达到500亿美元，反映出对快速检测解决方案的需求大幅增加。这一增长可能推动微流控技术的采用，因为它们提供了有效即时应用所需的精确度和速度。随着医疗系统越来越重视即时诊断能力，全球市场预计将蓬勃发展。 - 世界银行健康指标显示，初级医疗和去中心化诊断服务在新兴和发达经济体中的投资不断增加。扩大医疗可及性正在鼓励便携式即时技术的快速采用，使微流控设备成为更快的诊断和治疗决策的必要工具。 ### Increasing Investment in Research and Development 微流控设备市场受益于各个领域，包括医疗、制药和生物技术的研发投资不断增加。这项投资对微流控技术的创新和提升至关重要，这些技术对于开发新的诊断工具和治疗解决方案至关重要。各国政府和私营实体正在分配大量资源来推进微流控研究，资金水平每年达到数十亿美元。 这一资金的涌入可能加速新型微流控应用的开发，从而扩大全球市场。此外，随着研究机构和公司合作探索微流控领域的新前沿，全球行业预计将经历强劲增长，推动尖端技术和解决方案的引入。 - 世界银行创新指标显示，全球研发支出持续增长，许多发达经济体在研究活动中投资超过GDP的2%。对生物技术、生命科学和医疗技术创新的资金增加正在支持下一代微流控平台的持续发展。 ## Future Outlook 全球微流体设备市场规模预计到2035年将达到185亿美元，年均增长率为9.25%，得益于诊断、药物递送和芯片实验室技术的进步。 到2035年，全球微流体设备市场预计将保持强劲，反映出显著的增长和创新。 ## Segment Insights ### 按应用：体外诊断（最大）与即时检测（增长最快） 微流控设备市场展示了多样的应用格局，体外诊断（IVD）、药物递送、即时检测（POCT）和生物医学研究等领域贡献显著。IVD目前在微流控市场中占据59%的最大份额，得益于其在准确高效地检测各种疾病和状况中的广泛应用。紧随其后的是POCT的新兴应用，因其能够在关键情况下提供快速和分散的检测解决方案而获得了动力。 赛默飞世尔科技通过先进的检测平台和微流控测试解决方案不断扩展诊断能力。到2024年，体外诊断约占微流控设备市场的59%，得益于全球对快速疾病检测、生物标志物分析和精准诊断应用的需求不断增加。 ### 按材料类型：聚合物（最大）与玻璃（增长最快） 微流控设备市场受到材料类型的显著影响，聚合物因其多功能性、成本效益和易于制造而占据64%的最大份额。由于其在设计和性能上的适应性，它们在众多应用中被广泛使用。紧随其后，玻璃材料的市场存在感不断增强，因为它们提供优越的光学清晰度和稳定性，使其在诊断和分析程序中的高精度应用中理想。 安捷伦科技继续支持基于聚合物的微流控系统的创新，因其制造灵活性和成本效率。到2024年，聚合物材料在市场中占据约64%的份额，得益于在临床诊断、生物医学研究和即时检测应用中的广泛采用。 ### 按技术：压力驱动（最大）与电动流体（增长最快） 微流控设备市场主要由压力驱动技术主导，占据61%的显著份额，因其在生物医学和诊断领域的广泛应用而受到青睐。该细分市场能够精确控制流体流动，使其成为研究人员和微流控芯片制造商的首选，在全球行业中建立了坚实的立足点。同时，电动流体细分市场正在获得关注，被认为是增长最快的技术，得益于允许更灵活和可控流体操作的创新。 技术：压力驱动（主导）与电动流体（新兴） 微流控设备中的压力驱动技术以其在泵基系统中的可靠性和效率为特征，使其成为全球行业的主导力量。该技术特别适用于需要高通量和精确流体管理的应用，如细胞分选和生化检测。相反，电动流体技术作为一种新兴趋势，利用电场在微观尺度上操控流体，展示了其在实验室芯片设备等应用中的潜力。实验室对自动化和小型化的日益关注正在推动电动流体技术的发展，预示着未来几年快速的进步和日益的采用。 ### 按最终用途：医疗保健（最大）与制药（增长最快） 微流控设备市场在最终用途细分中显示出动态分布，医疗保健处于领先地位。该细分市场占据全球行业的66%，得益于即时诊断和个性化医疗的进步。制药行业代表了一个快速扩展的细分市场，越来越多地被用于药物开发过程和生物研究。它们的整合促进了高通量筛选，并提高了医学的精确性，在全球行业中占据了显著份额。 医疗保健：主导与制药：新兴 医疗保健部门在微流控设备市场中仍然占据主导地位，反映出对诊断工具和临床应用的强劲需求。医疗保健中的微流控设备在实验室检测、疾病检测和患者监测中至关重要，其特点是能够快速准确地进行复杂分析。另一方面，制药细分市场正在迅速崛起，推动药物发现和开发中的创新需求。微流控技术允许在实验室环境中实现小型化和自动化，从而加快结果并降低成本，标志着其在革命性制药检测和研究中的关键角色。 ## Regional Market Share Analysis 微流体设备市场在各个地区都经历了显着增长。受医疗保健进步以及微流控技术在诊断和治疗领域的日益采用的推动，北美在微流控设备市场规模方面处于领先地位，到 2024 年将占全球收入的 44.35% 以上。 - CDC 数据显示，慢性病约占美国年度医疗保健支出的 90%，这增强了对先进诊断技术和快速检测解决方案的需求。这种日益增长的医疗保健负担继续支持微流体设备在整个北美的临床和研究应用中的广泛采用。 受益于强劲的研发举措，欧洲微流控设备市场规模到 2024 年将达到 18 亿美元，占据 25.75% 的份额，成为第二大区域市场。 - 根据欧洲疾病预防和控制中心的数据，欧洲支持覆盖超过 4.5 亿人口的医疗保健系统，并越来越注重诊断和创新。这推动了先进微流体技术在研究和临床环境中的采用。 亚太地区的估值也很重要，2024 年估值为 25 亿美元，预计到 2035 年将增长至 65 亿美元，凸显了中国和印度等国家不断扩大的生物技术行业和医疗保健进步。 - GE Healthcare 继续投资于精密诊断、分子测试技术和数字医疗解决方案，以补充微流体创新。这些投资支持更快的临床决策、提高诊断准确性以及在北美医疗保健系统中更广泛地采用先进的医疗保健技术。 南美洲的市场规模在 2024 年为 4 亿美元，中东和非洲的市场规模为 19 亿美元，虽然市场规模较小，但由于医疗基础设施投资的增加，它们显示出了增长潜力。总体而言，区域细分揭示了对市场动态、增长机会和推动市场的趋势的重要见解。 ## Competitive Benchmarking The competitive landscape of the Microfluidic Devices Market is characterized by a multitude of key microfluidic manufacturers striving to enhance their market presence through innovation, strategic partnerships, and technological advancements. Microfluidic companies within this market focus on integrating microfluidic technology into applications ranging from diagnostics to drug delivery, capitalizing on the increasing demand for point-of-care testing and personalized medicine.   Competitive dynamics are influenced by factors such as product innovation, regulatory approvals, and the ability to meet diverse customer needs. As microfluidic manufacturers aim to capture larger shares, they are also engaging in collaborations and mergers that enhance their research capabilities and market reach, further intensifying competition. Its robust R&D capabilities enable F. HoffmannLa Roche to frequently introduce advanced products that align with microfluidic market trends and emerging healthcare challenges. Additionally, the microfluidic company’s well-established distribution networks and strategic partnerships have facilitated a significant presence in various regions, allowing for broader access to its microfluidic solutions.   The commitment to regulatory compliance and quality assurance also enhances its credibility and trust among healthcare professionals and stakeholders. Oxford Nanopore Technologies has made notable strides within the market by offering groundbreaking products that cater to diverse applications in genomics and diagnostics. The microfluidic company stands out with its innovative sequencing technology that operates at the nanoscale, allowing for rapid and cost-effective genomic analysis.   Oxford Nanopore Technologies benefits from a unique position within the market due to its flexible and scalable devices, which integrate seamlessly into various laboratory workflows. The microfluidic company has gained substantial traction through strategic mergers and acquisitions that bolster its technological capabilities and expand its product portfolio. Its strong emphasis on customer collaboration and continuous improvement further solidifies its market position. Overall, Oxford Nanopore Technologies is recognized for its cutting-edge advancements and robust presence in the global landscape of microfluidic devices. ## Recent News & Developments The first dissolvable microfluidic transduction enhancer for in vitro lentivirus-mediated gene delivery, the Lenti-X Transduction Sponge, was introduced by Takara Bio Inc. in May 2024. It allows for high-efficiency transduction across a variety of cell types with a walk-away process. At the Protein & Antibody Engineering Summit in Boston in May 2024, RedShiftBio unveiled their Aurora TX device, which combines thermal ramping capabilities with sophisticated microfluidic modulation spectroscopy to improve biomolecular stability monitoring. In response to increasing demand, uFluidix increased its thermoplastic microfluidic chip production capacity in January 2024 and optimized procedures to increase throughput and quality. On April 3, 2024, Affinity Biosensors received FDA clearance for its LifeScale AST system—a microfluidic diagnostic device delivering rapid antibiotic susceptibility testing for bacteremia. Parallel Fluidics successfully concluded a US$7 million seed round on November 7, 2024, with the goal of commercializing its MV‑2 high-speed commercial microfluidic devices through an on-demand design and manufacturing platform. Microfluidic chip manufacturers such as 3M, DuPont, Gerresheimer, and ZEON increased their roll-to-roll (R2R) production of film-based microfluidic cartridges with improved surface chemistries for point-of-care microfluidic diagnostics during 2025. In order to grow enzymatic assay platforms, Dolomite Microfluidics improved chip-production lines in 2025 with precision robots and AI-driven quality control. throughout order to improve supply chain resilience, Agilent Technologies has extended regional microfluidic production centers throughout North America and Europe. ## Report Scope | MARKET SIZE 2024 | 6.99(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.637(USD Billion) | | MARKET SIZE 2035 | 18.5(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.25% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Danaher Corporation (US), PerkinElmer (US), Fluidigm Corporation (US), Bio-Rad Laboratories (US), MilliporeSigma (US), Micronit Microfluidics (NL), Dolomite Microfluidics (GB) | | Segments Covered | Applications, Material Type, Technology, End-use, Regional | | Key Market Opportunities | Advancements in point-of-care diagnostics drive growth in the market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Microfluidic Devices Market in 2035?** A: The market is projected to reach a valuation of 18.5 USD Billion by 2035. **Q: What was the market valuation for Microfluidic Devices in 2024?** A: In 2024, the overall market valuation for Microfluidic Devices was 6.99 USD Billion. **Q: What is the expected CAGR for the Microfluidic Devices Market from 2025 to 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 9.25%. **Q: Which application segment is anticipated to grow the most in the Microfluidic Devices Market?** A: The In Vitro Diagnostics segment is expected to grow from 2.1 USD Billion in 2024 to 5.5 USD Billion by 2035. **Q: What are the key materials used in Microfluidic Devices, and how are they projected to perform?** A: Polymer is projected to grow from 2.79 USD Billion in 2024 to 7.25 USD Billion by 2035, indicating strong demand. **Q: Which technology segment is likely to see significant growth in the Microfluidic Devices Market?** A: The Capillary-driven technology segment is expected to increase from 2.0 USD Billion in 2024 to 5.2 USD Billion by 2035. **Q: What end-use sectors are driving the Microfluidic Devices Market?** A: The Healthcare sector is projected to grow from 2.5 USD Billion in 2024 to 6.5 USD Billion by 2035, highlighting its importance. **Q: Who are the leading companies in the Microfluidic Devices Market?** A: Key players in the market include Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies. **Q: How does the Drug Delivery segment perform in the Microfluidic Devices Market?** A: The Drug Delivery segment is expected to grow from 1.5 USD Billion in 2024 to 4.0 USD Billion by 2035. **Q: What is the projected growth for the Point Of Care Testing segment in the Microfluidic Devices Market?** A: The Point Of Care Testing segment is anticipated to increase from 1.8 USD Billion in 2024 to 4.5 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/microfluidic-devices-market-954*